Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. - Wikidata - awgldk - TriplyDB

Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach.

Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach.

http://www.wikidata.org/entity/Q40141995

about

Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies The role of tau in neurodegenerative diseases and its potential as a therapeutic target Prion-like properties of Tau protein: the importance of extracellular Tau as a therapeutic target Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models The structure of human tau-tubulin kinase 1 both in the apo form and in complex with an inhibitor The Role of MAPT in Neurodegenerative Diseases: Genetics, Mechanisms and Therapy Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency Early investigational drugs targeting tau protein for the treatment of Alzheimer's disease Cholesterol 24-hydroxylase defect is implicated in memory impairments associated with Alzheimer-like Tau pathology.Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis.Tau-tubulin kinase 1 expression, phosphorylation and co-localization with phospho-Ser422 tau in the Alzheimer's disease brain.Antibody-derived in vivo imaging of tau pathology.Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy Identification of the sites of tau hyperphosphorylation and activation of tau kinases in synucleinopathies and Alzheimer's diseases.Tau aggregation and its interplay with amyloid-β.Ectosomes: a new mechanism for non-exosomal secretion of tau protein.Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice.Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy Passive Immunization in JNPL3 Transgenic Mice Using an Array of Phospho-Tau Specific Antibodies.Doubly Phosphorylated Peptide Vaccines to Protect Transgenic P301S Mice against Alzheimer's Disease Like Tau Aggregation.Stabilization of Microtubule-Unbound Tau via Tau Phosphorylation at Ser262/356 by Par-1/MARK Contributes to Augmentation of AD-Related Phosphorylation and Aβ42-Induced Tau Toxicity.A fresh perspective from immunologists and vaccine researchers: active vaccination strategies to prevent and reverse Alzheimer's disease.Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer's Disease and Other Tauopathies.Advances in the development of vaccines for Alzheimer's disease.Tau as a therapeutic target in neurodegenerative disease.Prion-like propagation of protein aggregation and related therapeutic strategies.Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology Antibody uptake into neurons occurs primarily via clathrin-dependent Fcγ receptor endocytosis and is a prerequisite for acute tau protein clearance.Therapeutic strategies for tau mediated neurodegeneration.Tau passive immunization inhibits not only tau but also Aβ pathology Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies."Prion-like" templated misfolding in tauopathies.Tau immunotherapy and imaging.Alzheimer disease therapy--moving from amyloid-β to tau.Alzheimer disease therapeutics: focus on the disease and not just plaques and tangles Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward.Harnessing the immune system for treatment and detection of tau pathology.Tau-based therapeutic approaches for Alzheimer's disease - a mini-review.

P2860

Q26769957-4FEB8709-A91B-4DC2-AC79-91D4288E61C2 Q27005032-B5D36CBE-48AD-433F-B165-80D9EF8BAE8C Q27021159-8C57524C-84DB-4815-9216-2D3AF2900D7F Q27308146-BDB40B4F-3788-4E04-8D6F-A07543113AD0 Q27682266-3E801168-133F-449B-9EEC-19E785F1D6D4 Q28119005-CF82FFD7-534D-4E23-BA6C-B09FA1F1223A Q30578913-914CF666-C4D5-4264-8267-44280B86CE41 Q33640390-743AEE33-227B-4611-96A1-CB75188B8252 Q33887379-011EB383-7485-4FAA-8D6C-9E4B296A0DC0 Q34044871-F0C696AB-752F-4677-9D93-A247DA068FE8 Q34205027-F3B17279-60D6-4A16-98F0-AA05A49D6860 Q34307528-DEB50C33-2CA1-47D4-8485-E34581AF7710 Q34664345-54662892-7527-41D1-8860-BA817D401F43 Q34973787-CDA5E1B3-FDB0-4762-A90D-9E50FD681C86 Q35000764-BE1F214C-714A-44BD-9CFE-95960ED99B78 Q35008256-F04464F4-E58A-47D0-9993-53A17B40D6D7 Q35196319-189D4770-5BDF-492B-861D-F0004A671832 Q35204878-36EE6B55-57A1-41F4-BB8B-72A723F24F5A Q35544737-9F57429E-A104-4E9B-AACF-B641DE34D2F5 Q35745135-4CE1ED5B-AF3D-4B52-A214-A64A1E9FCBB9 Q35826638-2FB57324-BC22-466E-A56F-2924B593B56F Q35972860-C5C8706E-9F61-4640-9B3A-BA6BB48D8E4B Q36240389-0CDB1E42-FF09-44C6-A295-DCBEC41491AB Q36484413-A6FE5FEC-ED7B-42D4-BC8C-918CCE4C2A73 Q36558485-78E1A8A5-E132-49DA-B992-4953D5FDED71 Q36965988-357BC6E5-A5A3-41BB-AD06-0DBC1F9DD589 Q36970350-D7D6D461-467C-42F4-B05D-CCF695EC939E Q36983208-61050843-CD37-4755-9B1B-647AE09177C1 Q37311364-367CD8F7-FE5A-48E3-BA5B-A1858F08FA3F Q37368709-2413D643-C371-43A1-8FB5-0D7374942A06 Q37550818-48A352C4-B1F1-4F8E-B1F5-97FA301156FF Q37579019-71786E60-0CDB-4B13-AE36-542841F546BF Q38079317-2BB91178-B8EC-4633-A60E-B6298820986C Q38099071-2BC49179-746D-4869-A3C2-B9F45A3394C2 Q38136880-E82F4EBE-9782-40EF-88E7-59359623B58C Q38161786-0D63EDD9-002F-4F91-B04A-916C0FCCEB0B Q38177975-819F416F-24AF-4D2C-94A6-BC18A53A9AD0 Q38184618-AA5571CB-CC20-494B-A918-247ED753566A Q38194049-823E4EA0-7D78-43B8-B778-4FCD513E0C96 Q38204620-352DD0E6-485C-469C-A929-0326BCB33787

P2860

Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach.

http://www.wikidata.org/entity/Q40141995

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Targeting phospho-Ser422 by ac ...... suitable therapeutic approach.

@en

type

label

Targeting phospho-Ser422 by ac ...... suitable therapeutic approach.

@en

prefLabel

Targeting phospho-Ser422 by ac ...... suitable therapeutic approach.

@en

P1433

Q40141995-A121DBCB-21F3-4A3D-BC68-9D80111A3A81

P1476

Q40141995-2BF14A9A-E37B-471D-86E7-19D2EC79733E

P2093

Q40141995-01266B39-1FA2-4912-B7DD-5478DB83EB4D

Q40141995-0A48445A-637D-4352-A88E-EF8415FE10A4

Q40141995-0FEF1745-9471-4A23-BD34-106036F06398

Q40141995-5D083D35-DC0F-48F5-B314-65935041D4CB

Q40141995-6AAFA7F3-DB84-4FB8-B10A-3B1E2945B830

Q40141995-6F985D19-65DB-4A68-A611-32C62DD4721C

Q40141995-A2A7132E-3D3C-41F8-A71D-842C54D7ED9A

Q40141995-CA6030A7-6E01-478F-938D-9FB9D4384B1B

Q40141995-EBE86D5D-2AEC-4B49-A3FF-6C322857FB09

Q40141995-FF035319-6017-447A-9B91-B2E4DC17D055

P2860

Q40141995-0FA44CFD-2028-4986-8170-EE1AC3605475

Q40141995-1342D60B-D918-4956-8F12-F45FB66564A2

Q40141995-1902F419-60CF-4FA8-A707-80CA8F2C7945

Q40141995-1BCE0651-20F1-4102-84CC-1CB2D4D87D43

Q40141995-1DA3A5CE-926B-4A1C-AB96-9C4E6F89E2EC

Q40141995-27476931-0241-4872-A299-41BCA288F2D1

Q40141995-2D289447-F910-45F7-869E-5EBA62E29DE6

Q40141995-36F2329D-5066-47D6-B1FA-15F3B5CB15FA

Q40141995-3ED39C88-C9BE-4DBD-BD72-CB4CE642AC27

Q40141995-44E70159-AFAD-458A-95E2-905ECBC07554

P304

Q40141995-E2647D7F-730E-4BCD-99B8-385DFDC3097B

P31

Q40141995-332ACCE2-7026-437C-AD2D-9D61B7039C74

P356

Q40141995-0E53E9A5-7BFD-4EE5-B189-78C851520570

P433

Q40141995-B17B74D1-3599-4526-99D6-E0520C0EAB6D

P478

Q40141995-FF501543-DD4E-4963-9EC2-E616645D5DA5

P50

Q40141995-1EDFB0EC-888D-42E4-9940-1FB8F4890D9D

P577

Q40141995-EAAC7292-DF4A-42A9-9817-642864FEA83C

P698

Q40141995-7AAC6112-4E47-4BD0-B760-9A083634FF69

P921

Q40141995-730AFBB8-4791-4E05-9566-75BC913DEF9F

P932

Q40141995-785B2AF7-8336-4915-A501-EF03EBC1530F

P356

156720512800492503

P1433

Current Alzheimer Research

P1476

Targeting phospho-Ser422 by ac ...... suitable therapeutic approach.

@en

P2093

David Blum

http://www.w3.org/2001/XMLSchema#string

Francisco J Fernandez-Gomez

http://www.w3.org/2001/XMLSchema#string

Laetitia Troquier

http://www.w3.org/2001/XMLSchema#string

Luc Buee

http://www.w3.org/2001/XMLSchema#string

Marie-Eve Grosjean

http://www.w3.org/2001/XMLSchema#string

Nadege Zommer

http://www.w3.org/2001/XMLSchema#string

Nicolas Sergeant

http://www.w3.org/2001/XMLSchema#string

Raphaelle Caillierez

http://www.w3.org/2001/XMLSchema#string

Susanna Schraen-Maschke

http://www.w3.org/2001/XMLSchema#string

Sylvie Burnouf

http://www.w3.org/2001/XMLSchema#string

P2860

Transmission and spreading of tauopathy in transgenic mouse brain

Active and passive immunotherapy for neurodegenerative disorders

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits.

Early axonopathy preceding neurofibrillary tangles in mutant tau transgenic mice.

Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology

Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau.

Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin.

Getting into the brain: approaches to enhance brain drug delivery.

Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model

P304

397-405

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2174/156720512800492503

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Susanna Schraen-Maschke

P577

2012-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22272619

http://www.w3.org/2001/XMLSchema#string

P921

P932

3637173

http://www.w3.org/2001/XMLSchema#string